Comparative Post-Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database

Basit Öğe Kaydı
dc.authorid0000-0002-7822-3154
dc.contributor.authorAksoyalp, Zinnet Sevval
dc.contributor.authorNemutlu-Samur, Dilara
dc.date.accessioned2026-01-24T12:30:49Z
dc.date.available2026-01-24T12:30:49Z
dc.date.issued2024
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractObjectivesThe aim of this study was to conduct a comparative analysis of the proportion of cardiovascular adverse events (AEs) associated with the utilization of memantine and cholinesterase inhibitors and to highlight the potential impact of sex differences in these AEs.MethodsCardiac and vascular disorders AEs with antidementia medications were obtained from the FDA Adverse Event Reporting System database. The reporting odds ratio and its corresponding 95% confidence intervals were calculated. The chi-squared test was used to evaluate differences in categorical variables, and a two-way ANOVA followed by a Bonferroni post-test was used to compare the AEs reported for antidementia medications.ResultsMemantine was associated with 544 selected cardiac and vascular disorder AEs. A signal for bradycardia, myocardial infarction, atrial fibrillation and cardiac arrest has been observed in patients receiving choline esterase inhibitors compared to those receiving memantine. On the other hand, cardiac failure and deep vein thrombosis AEs were found to be more common in patients receiving memantine. The majority of reported cardiac and vascular AEs were reported more frequently in female patients. More cases of cardiac failure, cardiac arrest, and deep vein thrombosis were reported in females than males taking memantine, but bradycardia was more common in males than females.ConclusionHealthcare professionals should be aware of the potential for cardiovascular AEs during treatment with antidementia medications and the possibility of sex differences in this regard. Memantine differs from cholinesterase inhibitors in terms of cardiovascular AEs, and there may be sex-related differences in the proportion of these AEs.
dc.identifier.doi10.1002/gps.70018
dc.identifier.issn0885-6230
dc.identifier.issn1099-1166
dc.identifier.issue11
dc.identifier.pmid39562528
dc.identifier.scopus2-s2.0-85210072943
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1002/gps.70018
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5453
dc.identifier.volume39
dc.identifier.wosWOS:001370296600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal of Geriatric Psychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectadverse events
dc.subjectcardiovascular
dc.subjectcholine esterase inhibitors
dc.subjectdementia
dc.subjectdonepezil
dc.subjectgalantamine
dc.subjectmemantine
dc.subjectrivastigmine
dc.subjectsafety
dc.subjectsex differences
dc.titleComparative Post-Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu